From a molecular clinical viewpoint, Relafen 750 (Naproxen) exhibits particular properties . It operates primarily as a NSAID agent, preferentially inhibiting cyclooxygenase-2 (COX-2), an enzyme participating in prostaglandin formation. This focused inhibition results in diminished inflammation and discomfort , providing therapeutic effects for sub